• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Lumicell raises $21m for image-guided cancer surgery tech

October 24, 2017 By Sarah Faulkner

Lumicell has raised $20.7 million over the past three months, according to a regulatory document filed with SEC last week.

More than 20 investors have contributed to the $26.5 million equity offering, the Wellesley, Mass.-based company reported, including one investor outside of the U.S.

In September, the company announced that it plans to study its Lum image-guided cancer surgery system in clinical studies for breast cancer and prostate cancer.

The breast cancer trial is a pivotal study following an initial training period with surgeons, Lumicell reported, and the prostate cancer study is a first for Lumicell and its technology.

The Lum system has a drug, device and decision software component that work together, in real-time, to guide cancer surgeons in the detection and removal of cancer cells during surgery. With the start of these two trials, the Lum system is being assessed in five solid tumor indications.

The breast cancer and prostate cancer trials are supported by clinical feasbility data that the company touted earlier last year, showing that the Lum system achieved 100% detection of residual cancer. Lumicell is expecting to report additional clinical data in breast cancer later this year, the company said.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Lumicell

IN CASE YOU MISSED IT

  • MiniMed claims quick FDA clearance for Fit patch pump
  • Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
  • Senseonics delivers ‘breakout quarter’ more than doubling Eversense 365 revenue
  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS